- Academic Editor
-
-
-
Announcements
Open Access
Review
An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma
Show Less
1
Department of Surgery, Bengbu Medical College, 233030 Bengbu, AnHui, China
2
General Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, 310000 Hangzhou, Zhejiang, China
*Correspondence: taohdac9@yahoo.com (Ran Tao)
†These authors contributed equally.
†These authors contributed equally.
Front. Biosci. (Landmark Ed) 2023, 28(12), 361;
https://doi.org/10.31083/j.fbl2812361
Submitted: 1 June 2023 | Revised: 22 July 2023 | Accepted: 10 August 2023 | Published: 29 December 2023
(This article belongs to the Special Issue New Targets in Anticancer Therapy)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract
Pancreatic cancer is the seventh leading cause of cancer-related deaths, and chemotherapy is one of the most important treatments for pancreatic cancer. Unfortunately, pancreatic cancer cells can block chemotherapy drugs from entering the tumor. This is owing to interactions between the tumor’s environment and the cancer cells. Here, we review the latest research on the mechanisms by which pancreatic cancer cells block the chemotherapy drug, gemcitabine. The results of our review can help identify potential therapeutic targets for the blocking of gemcitabine by pancreatic cancer cells and may provide new strategies to help chemotherapy drugs penetrate tumors.
Keywords
pancreatic cancer
chemotherapy resistance
chemosensitization
tumor microenvironment
gemcitabine
Funding
A-2019-W153/Provincial Health Ministry Major 2020
Figures
Fig. 1.